

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

August 18, 2023

<u>Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL</u> <u>Availability Notice</u>

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that our **Dipyridamole Injection**, **USP 5 mg/mL SD Vial 10 mL** will be available at all distribution centres by **August 23, 2023**. Once available, this product will be placed on allocation.

Due to the timing of when replenishment inventory will arrive and the criticality of this medication, allocations will be made available on a <u>weekly basis</u> and are built using 100% historical monthly demand (e.g., 4 packs of historical monthly demand = an allocation of 1 pack per week). Please note that any unused allocations <u>will not be carried forward</u> from week to week. Allocations in place include limited coverage of Glenwood customers' (Persantine) demand and limited inventory may be available to customers who do not have an allocation.

We are working diligently to ensure equitable distribution of the limited product we have available at this time and appreciate your patience and understanding during this supply challenge.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Availability Date Allocations
02244475	C601310	921014	600262	Dipyridamole Injection, USP 5 mg/mL SD Vial 10 mL	At all distribution centres by: Aug. 23, 2023 Allocations to be available on a
					weekly basis using 100% historical monthly demand.

For any questions or concerns, please don't hesitate to contact your sales representative.

Sincerely,

Joseph Le

Senior Manager, Commercial Operations & Analytics

joseph.le@fresenius-kabi.com